<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05290000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q13133</UniProt_ID>
  <Seq_Length>447</Seq_Length>
  <Molecule_Weight>50396</Molecule_Weight>
  <KEGG_ID>hsa:10062</KEGG_ID>
  <Orthology_ID>K08536</Orthology_ID>
  <EBI_ID>EBI-781356</EBI_ID>
  <Function_Summary>Orphan receptor. Interaction with RXR shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (By similarity).</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 1 group H member 3</Alias>
      <Alias>Liver X receptor alpha</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a activating transcription factor and also with the basal transcription machinery in order to increase the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription coactivator activity</Keyword>
      <Ontology_ID>GO:0003713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the sterol response element (SRE), a nonpalindromic sequence found in the promoters of genes involved in lipid metabolism.</Detail>
      <Keyword>Sterol response element binding</Keyword>
      <Ontology_ID>GO:0032810</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with cholesterol (cholest-5-en-3-beta-ol); the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Cholesterol binding</Keyword>
      <Ontology_ID>GO:0015485</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>A ligand-dependent receptor found in the nucleus of the cell.</Detail>
      <Keyword>Ligand-dependent nuclear receptor activity</Keyword>
      <Ontology_ID>GO:0004879</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>52</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a protein, occurring at the level of an individual cell.</Detail>
      <Keyword>Positive regulation of cellular protein metabolic process</Keyword>
      <Ontology_ID>GO:0032270</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of pancreatic juice secretion, the regulated release of pancreatic juice by the exocrine pancreas into the upper part of the intestine.</Detail>
      <Keyword>Negative regulation of pancreatic juice secretion</Keyword>
      <Ontology_ID>GO:0090188</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of a circadian rhythm. A circadian rhythm is a biological process in an organism that recurs with a regularity of approximately 24 hours.</Detail>
      <Keyword>Regulation of circadian rhythm</Keyword>
      <Ontology_ID>GO:0042752</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage activation.</Detail>
      <Keyword>Negative regulation of macrophage activation</Keyword>
      <Ontology_ID>GO:0043031</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a progesterone stimulus.</Detail>
      <Keyword>Response to progesterone stimulus</Keyword>
      <Ontology_ID>GO:0032570</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell.</Detail>
      <Keyword>Cholesterol homeostasis</Keyword>
      <Ontology_ID>GO:0042632</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol.</Detail>
      <Keyword>Positive regulation of triglyceride biosynthetic process</Keyword>
      <Ontology_ID>GO:0010867</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell or group of cells.</Detail>
      <Keyword>Negative regulation of secretion of lysosomal enzymes</Keyword>
      <Ontology_ID>GO:0090341</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.</Detail>
      <Keyword>Negative regulation of macrophage derived foam cell differentiation</Keyword>
      <Ontology_ID>GO:0010745</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency or rate of receptor biosynthesis. Receptor biosynthesis is the collection of chemical reactions and pathways resulting in the formation of a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</Detail>
      <Keyword>Positive regulation of receptor biosynthetic process</Keyword>
      <Ontology_ID>GO:0010870</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of the series of molecular events generated as a consequence of interferon-gamma binding to a cell surface receptor.</Detail>
      <Keyword>Negative regulation of interferon-gamma-mediated signaling pathway</Keyword>
      <Ontology_ID>GO:0060336</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids.</Detail>
      <Keyword>Positive regulation of fatty acid biosynthetic process</Keyword>
      <Ontology_ID>GO:0045723</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes.</Detail>
      <Keyword>Negative regulation of pinocytosis</Keyword>
      <Ontology_ID>GO:0048550</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Negative regulation of cholesterol storage</Keyword>
      <Ontology_ID>GO:0010887</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of toll-like receptor 4 signaling pathway.</Detail>
      <Keyword>Positive regulation of toll-like receptor 4 signaling pathway</Keyword>
      <Ontology_ID>GO:0034145</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cholesterol homeostasis.</Detail>
      <Keyword>Positive regulation of cholesterol homeostasis</Keyword>
      <Ontology_ID>GO:2000189</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the activity of the enzyme lipoprotein lipase.</Detail>
      <Keyword>Positive regulation of lipoprotein lipase activity</Keyword>
      <Ontology_ID>GO:0051006</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of triglyceride within an organism or cell.</Detail>
      <Keyword>Triglyceride homeostasis</Keyword>
      <Ontology_ID>GO:0070328</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response.</Detail>
      <Keyword>Negative regulation of inflammatory response</Keyword>
      <Ontology_ID>GO:0050728</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte.</Detail>
      <Keyword>Apoptotic cell clearance</Keyword>
      <Ontology_ID>GO:0043277</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Negative regulation of lipid transport</Keyword>
      <Ontology_ID>GO:0032369</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.</Detail>
      <Keyword>Cellular response to lipopolysaccharide</Keyword>
      <Ontology_ID>GO:0071222</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.</Detail>
      <Keyword>Positive regulation of cholesterol efflux</Keyword>
      <Ontology_ID>GO:0010875</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MSLWLGAPVPDIPPDSAVELWKPGAQDASSQAQGGSSCILREEARMPHSAGGTAGVGLEAAEPTALLTRAEPPSEPTEIRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCEGCKGFFRRSVIKGAHYICHSGGHCPMDTYMRRKCQECRLRKCRQAGMREECVLSEEQIRLKKLKRQEEEQAHATSLPPRASSPPQILPQLSPEQLGMIEKLVAAQQQCNRRSFSDRLRVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDFAKQLPGFLQLSREDQIALLKTSAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIFEFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDRLMFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE</Protein_Seq>
    <DNA_Seq>AGGAAGGAGGGGTGGCCTGACCCCTCGGCAGTCCCTCCCCTCAGCCTTTCCCCAAATTGCTACTTCTCTGGGGCTCCAGGTCCTGCTTGTGCTCAGCTCCAGCTCACTGGCTGGCCACCGAGACTTCTGGACAGGAAACTGCACCATCCTCTTCTCCCAGCAAGGGGGCTCCAGAGACTGCCCACCCAGGAAGTCTGGTGGCCTGGGGATTTGGACAGTGCCTTGGTAATGACCAGGGCTCCAGGAAGAGATGTCCTTGTGGCTGGGGGCCCCTGTGCCTGACATTCCTCCTGACTCTGCGGTGGAGCTGTGGAAGCCAGGCGCACAGGATGCAAGCAGCCAGGCCCAGGGAGGCAGCAGCTGCATCCTCAGAGAGGAAGCCAGGATGCCCCACTCTGCTGGGGGTACTGCAGGGGTGGGGCTGGAGGCTGCAGAGCCCACAGCCCTGCTCACCAGGGCAGAGCCCCCTTCAGAACCCACAGAGATCCGTCCACAAAAGCGGAAAAAGGGGCCAGCCCCCAAAATGCTGGGGAACGAGCTATGCAGCGTGTGTGGGGACAAGGCCTCGGGCTTCCACTACAATGTTCTGAGCTGCGAGGGCTGCAAGGGATTCTTCCGCCGCAGCGTCATCAAGGGAGCGCACTACATCTGCCACAGTGGCGGCCACTGCCCCATGGACACCTACATGCGTCGCAAGTGCCAGGAGTGTCGGCTTCGCAAATGCCGTCAGGCTGGCATGCGGGAGGAGTGTGTCCTGTCAGAAGAACAGATCCGCCTGAAGAAACTGAAGCGGCAAGAGGAGGAACAGGCTCATGCCACATCCTTGCCCCCCAGGGCTTCCTCACCCCCCCAAATCCTGCCCCAGCTCAGCCCGGAACAACTGGGCATGATCGAGAAGCTCGTCGCTGCCCAGCAACAGTGTAACCGGCGCTCCTTTTCTGACCGGCTTCGAGTCACGGTGATGCTTCTGGAGACATCTCGGAGGTACAACCCTGGGAGTGAGAGTATCACCTTCCTCAAGGATTTCAGTTATAACCGGGAAGACTTTGCCAAAGCAGGGCTGCAAGTGGAATTCATCAACCCCATCTTCGAGTTCTCCAGGGCCATGAATGAGCTGCAACTCAATGATGCCGAGTTTGCCTTGCTCATTGCTATCAGCATCTTCTCTGCAGACCGGCCCAACGTGCAGGACCAGCTCCAGGTAGAGAGGCTGCAGCACACATATGTGGAAGCCCTGCATGCCTACGTCTCCATCCACCATCCCCATGACCGACTGATGTTCCCACGGATGCTAATGAAACTGGTGAGCCTCCGGACCCTGAGCAGCGTCCACTCAGAGCAAGTGTTTGCACTGCGTCTGCAGGACAAAAAGCTCCCACCGCTGCTCTCTGAGATCTGGGATGTGCACGAATGACTGTTCTGTCCCCATATTTTCTGTTTTCTTGGCCGGATGGCTGAGGCCTGGTGGCTGCCTCCTAGAAGTGGAACAGACTGAGAAGGGCAAACATTCCTGGGAGCTGGGCAAGGAGATCCTCCCGTGGCATTAAAAGAGAGTCAAAGGGTTGCGAGTTTTGTGGCTACTGAGCAGTGGAGCCCTCGCTAACACTGTGCTGTGTCTGAAGATCATGCTGACCCCACAAACGGATGGGCCTGGGGGCCACTTTGCACAGGGTTCTCCAGAGCCCTGCCCATCCTGCCTCCACCACTTCCTGTTTTTCCCACAGGGCCCCAAGAAAAATTCTCCACTGTCAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Intestine</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Adrenals</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear chromatin</CellLocal>
      <Ontology_ID>GO:0000790</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>NR1H3</Gene_Name>
    <Gene_Alias>LXRA</Gene_Alias>
    <Gene_ID>10062</Gene_ID>
    <Genbank_ACCN>NM_001130101</Genbank_ACCN>
    <Protein_ACCN>NP_001123573</Protein_ACCN>
    <HGNC_ID>7966</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/10062</Gene_URL>
    <UCSC_ID>uc001nen.4</UCSC_ID>
    <EMBL_ID>ENSG00000025434</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>O60869</Uniprot_ID>
      <Gene_Name>EDF1</Gene_Name>
      <EBI_ID>EBI-781301</EBI_ID>
      <PPI_EBI_URL>EBI-781356,EBI-781301</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Acth-Secreting Pituitary Adenoma</Disease_Name>
      <Disease_Detail>Acth-Secreting Pituitary Adenoma</Disease_Detail>
      <Disease_DB>ACT010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acth_secreting_pituitary_adenoma?search=NR1H3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=NR1H3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myxoid Liposarcoma</Disease_Name>
      <Disease_Detail>Myxoid Liposarcoma</Disease_Detail>
      <Disease_DB>MYX005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myxoid_liposarcoma?search=NR1H3#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of the LXRalfa-RXRbeta LBD heterodimer</PDB_Title>
      <PDB_ID>1UHL</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UHL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation</PubMed_Title>
      <Author>Svensson, S., et al.</Author>
      <Journal>Embo J.(2003)22:4625-4633</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12970175?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of benzisoxazole synthetic agonist bound to the LXR-alpha</PDB_Title>
      <PDB_ID>3IPS</PDB_ID>
      <Resolution>2.26</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IPS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling.</PubMed_Title>
      <Author>Fradera, X., et al.</Author>
      <Journal>J.Mol.Biol.(2010)399:120-132</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20382159?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of benzisoxazole urea synthetic agonist bound to the LXR-alpha</PDB_Title>
      <PDB_ID>3IPU</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IPU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling.</PubMed_Title>
      <Author>Fradera, X., et al.</Author>
      <Journal>J.Mol.Biol.(2010)399:120-132</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20382159?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of GW3965 synthetic agonist bound to the LXR-alpha</PDB_Title>
      <PDB_ID>3IPQ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IPQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling.</PubMed_Title>
      <Author>Fradera, X., et al.</Author>
      <Journal>J.Mol.Biol.(2010)399:120-132</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20382159?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.dh.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1uhl</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Protein-induced</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>